Brinzolamide ophthalmic suspension + Azopt®
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Primary Open Angle Glaucoma
Conditions
Primary Open Angle Glaucoma, Ocular Hypertension
Trial Timeline
Dec 20, 2021 → Jan 6, 2023
NCT ID
NCT05022004About Brinzolamide ophthalmic suspension + Azopt®
Brinzolamide ophthalmic suspension + Azopt® is a phase 3 stage product being developed by Sun Pharmaceutical for Primary Open Angle Glaucoma. The current trial status is completed. This product is registered under clinical trial identifier NCT05022004. Target conditions include Primary Open Angle Glaucoma, Ocular Hypertension.
What happened to similar drugs?
20 of 20 similar drugs in Primary Open Angle Glaucoma were approved
Approved (20) Terminated (6) Active (0)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05022004 | Phase 3 | Completed |
Competing Products
20 competing products in Primary Open Angle Glaucoma